Esperion Therapeutics Inc - Asset Resilience Ratio
Esperion Therapeutics Inc (ESPR) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Esperion Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2023)
This chart shows how Esperion Therapeutics Inc's Asset Resilience Ratio has changed over time. See Esperion Therapeutics Inc (ESPR) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Esperion Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ESPR market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Esperion Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Esperion Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Esperion Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Esperion Therapeutics Inc (2002–2023)
The table below shows the annual Asset Resilience Ratio data for Esperion Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $205.80 Million | -- |
| 2022-12-31 | 16.97% | $42.09 Million | $247.94 Million | +3.76pp |
| 2021-12-31 | 13.22% | $50.44 Million | $381.59 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $353.26 Million | -- |
| 2019-12-31 | 16.16% | $34.65 Million | $214.45 Million | -52.89pp |
| 2018-12-31 | 69.05% | $99.05 Million | $143.45 Million | +9.40pp |
| 2017-12-31 | 59.65% | $165.73 Million | $277.83 Million | -11.07pp |
| 2016-12-31 | 70.72% | $173.42 Million | $245.21 Million | +25.07pp |
| 2015-12-31 | 45.65% | $134.93 Million | $295.57 Million | +31.14pp |
| 2014-12-31 | 14.51% | $20.80 Million | $143.34 Million | +10.01pp |
| 2013-12-31 | 4.50% | $3.53 Million | $78.29 Million | -3.97pp |
| 2002-12-31 | 8.47% | $4.35 Million | $51.41 Million | -- |
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more